| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -3.4 | -5.4 |
| EPS (diluted, $ a share) | $-0.14 | $-0.25 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ACTU. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Actuate Therapeutics, Inc.: key numbers
- Share price
- $0.2516Close, Nov 17
- Market cap
- $15.2M
- Shares outstanding
- 60.38MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Actuate Therapeutics, Inc.
All →Actuate Therapeutics Nasdaq/NYSE Compliance Notice
Actuate Therapeutics received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 26, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. This notice follows a separate July 2026 warning regarding the company's failure to meet the minimum market value of listed securities requirement.
- Counterparty
- The Nasdaq Stock Market LLC
- Term
- 180 days
Actuate Therapeutics President, CEO and Director Daniel M. Schmitt Buys $50K of Stock
Daniel M. Schmitt, President, CEO and Director, bought 140,844 shares of Actuate Therapeutics, Inc. at $0.355 a share, worth $50K in total on Oct 28, 2026. Shares held after the trade: 442,560 (+46.7%).
- Value
- $50K
- Shares
- 140,844
- Price
- $0.3550
- Role
- President, CEO and Director
- Holding change
- +46.7%
- Trade date
- Oct 28, 2026
Actuate Therapeutics Capital Raise of $11M
Actuate Therapeutics closed an underwritten public offering of 30,985,900 shares of common stock and warrants to purchase 15,492,950 shares, raising gross proceeds of approximately $11.0 million. The offering was priced at $0.71 per set of two shares and one warrant, implying a per-share price of $0.355. The company intends to use the net proceeds for working capital and general corporate purposes.
- Value
- $11M
- Counterparty
- Newbridge Securities Corporation